Ionis Pharmaceuticals, Inc. (BMV:IONS)
Mexico · Delayed Price · Currency is MXN | Market Cap | 152.78B +22.9% |
| Revenue (ttm) | 19.08B +47.5% |
| Net Income | -5.89B |
| EPS | -36.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8 |
| Open | 1,150.00 |
| Previous Close | 1,100.00 |
| Day's Range | 1,150.00 - 1,150.00 |
| 52-Week Range | 619.00 - 1,180.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ionis Pharmaceuticals price target lowered to $89 from $106 at Guggenheim
Guggenheim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $89 from $106 and keeps a Buy rating on the shares. The firm is revising some of its estimates…
Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data
Wolfe Research downgraded Ionis Pharmaceuticals (IONS) to Peer Perform from Outperform. Two trial disappointments – TTR and tau – nullified most of the firm’s prior bull thesis, while its remaining…
Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Ionis Pharmaceuticals (IONS) to Peer Perform from Outperform.
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage b...
Ionis to hold second quarter 2026 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second qua...
Ionis says Biogen presents Phase 2 CELIA data at AAIC
Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting t...
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigation...
Alnylam price target raised to $485 from $470 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Alnylam (ALNY) to $485 from $470 and keeps a Buy rating on the shares after AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) recently…
Ionis Pharmaceuticals price target lowered to $85 from $100 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $85 from $100 and keeps an Outperform rating on the shares. The company has an…
Ionis Pharmaceuticals doses first participant in Phase 1-2 ASCEND study
Ionis Pharmaceuticals (IONS) announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrom...
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-...
H.C. Wainwright trims Ionis price target, says trial failure reaction ‘overdone’
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $125 from $130 and keeps a Buy rating on the shares. The firm has cut…
Ionis Pharmaceuticals price target lowered to $110 from $130 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $110 from $130 and keeps an Overweight rating on the shares.
Ionis Pharmaceuticals price target lowered to $95 from $110 at Canaccord
Canaccord analyst Gary Nachman lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $110 and keeps a Buy rating on the shares. The firm and its partner…
Ionis Pharmaceuticals price target lowered to $90 from $115 at Barclays
Barclays lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $90 from $115 and keeps an Overweight rating on the shares after the company and partner AstraZeneca (AZN) announced…
Ionis Pharmaceuticals price target lowered to $100 from $115 at Citi
Citi analyst Eric Joseph lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $115 and keeps a Buy rating on the shares. The firm is updating its…
Ionis Pharmaceuticals price target lowered to $90 from $113 at Jefferies
Jefferies analyst Akash Tewari lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $90 from $113 and keeps a Buy rating on the shares after the CARDIO-TTRansform Phase 3…
Ionis Pharmaceuticals price target lowered to $86 from $105 at Needham
Needham analyst Joseph Stringer lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $86 from $105 and keeps a Buy rating on the shares after the company and partner…
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis , failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-...
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthy...
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evalu...
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Recordati (“Recordati”), under which Recordati obtained ...
Ionis Pharmaceuticals Transcript: FDA announcement
TRYNGOLZA received FDA approval as the first therapy to reduce triglycerides and acute pancreatitis risk in adults with sHTG, supported by robust phase III data showing up to 72% triglyceride reduction and 91% reduction in pancreatitis events. The launch will focus on high-risk patients, with broad payer access and strong support programs expected to drive adoption.